{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:31:12Z","timestamp":1792593072311,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070229"],"award-info":[{"award-number":["82070229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.neo.2024.100974","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T02:59:35Z","timestamp":1708052375000},"page":"100974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors"],"prefix":"10.1016","volume":"50","author":[{"given":"Xiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiqun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5548-1241","authenticated-orcid":false,"given":"Jingping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2024.100974_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.neo.2024.100974_bib0002","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.canlet.2017.11.020","article-title":"Targeting signaling pathways in multiple myeloma: pathogenesis and implication for treatments","volume":"414","author":"Hu","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.neo.2024.100974_bib0003","doi-asserted-by":"crossref","first-page":"e22341","DOI":"10.1096\/fj.202200354","article-title":"Chromosome 1 instability in multiple myeloma: aberrant gene expression, pathogenesis, and potential therapeutic target","volume":"36","author":"Luo","year":"2022","journal-title":"FASEB J."},{"key":"10.1016\/j.neo.2024.100974_bib0004","article-title":"New biological therapies for multiple myeloma","author":"Garfall","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.neo.2024.100974_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.neo.2024.100974_bib0006","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.neo.2024.100974_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2024.100974_bib0008","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1085\/jgp.8.6.519","article-title":"The metabolism of tumors in the body","volume":"8","author":"Warburg","year":"1927","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.neo.2024.100974_bib0009","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.neo.2024.100974_bib0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neo.2024.100974_bib0011","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beha.2007.09.003","article-title":"Bortezomib in multiple myeloma","volume":"20","author":"Mateos","year":"2007","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.neo.2024.100974_bib0012","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bjh.13172","article-title":"Recent advances and future directions in targeting the secretory apparatus in multiple myeloma","volume":"168","author":"Auner","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.neo.2024.100974_bib0013","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2018229118","article-title":"Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs","volume":"118","author":"Saavedra-Garcia","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neo.2024.100974_bib0014","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature14190","article-title":"Nutrient-sensing mechanisms and pathways","volume":"517","author":"Efeyan","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.neo.2024.100974_bib0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg's contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2024.100974_bib0016","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.neo.2024.100974_bib0017","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1158\/0008-5472.CAN-19-1789","article-title":"A tumor agnostic therapeutic strategy for hexokinase 1-null\/hexokinase 2-positive cancers","volume":"79","author":"Xu","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2024.100974_bib0018","doi-asserted-by":"crossref","unstructured":"Seyfried T.N. (2012). Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer. Editor (ed)^(eds): City.","DOI":"10.1002\/9781118310311"},{"key":"10.1016\/j.neo.2024.100974_bib0019","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1743-7075-7-7","article-title":"Cancer as a metabolic disease","volume":"7","author":"Seyfried","year":"2010","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.neo.2024.100974_bib0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: How? When?","volume":"133","author":"Zamagni","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.neo.2024.100974_bib0021","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1182\/blood-2005-12-4788","article-title":"Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth","volume":"107","author":"Doughty","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.neo.2024.100974_bib0022","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/imr.12732","article-title":"Plasma cells: you are what you eat","volume":"288","author":"D'Souza","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.neo.2024.100974_bib0023","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.it.2017.02.004","article-title":"The immunoregulatory roles of antibody glycosylation","volume":"38","author":"Jennewein","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.neo.2024.100974_bib0024","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.immuni.2016.06.011","article-title":"Mitochondrial pyruvate import promotes long-term survival of antibody-secreting plasma cells","volume":"45","author":"Lam","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.neo.2024.100974_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119857","article-title":"Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells","volume":"10","author":"Zub","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2024.100974_bib0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4067\/S0716-97602002000100004","article-title":"Glucose transporters: expression, regulation and cancer","volume":"35","author":"Medina","year":"2002","journal-title":"Biol. Res."},{"key":"10.1016\/j.neo.2024.100974_bib0027","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2011-09-377846","article-title":"Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy","volume":"119","author":"McBrayer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.neo.2024.100974_bib0028","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","article-title":"Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin","volume":"21","author":"Dalva-Aydemir","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2024.100974_bib0029","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1038\/sj.onc.1209603","article-title":"Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria","volume":"25","author":"Mathupala","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2024.100974_bib0030","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/0008-5472.CAN-18-2799","article-title":"An HK2 antisense oligonucleotide induces synthetic lethality in HK1(-)HK2(+) multiple myeloma","volume":"79","author":"Xu","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2024.100974_bib0031","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1073\/pnas.1212780110","article-title":"M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth","volume":"110","author":"Cortes-Cros","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neo.2024.100974_bib0032","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.tibs.2008.05.006","article-title":"New roles for pyruvate kinase M2: working out the Warburg effect","volume":"33","author":"Ferguson","year":"2008","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.neo.2024.100974_bib0033","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/ncb2120","article-title":"Components of the Hippo pathway cooperate with Nek2 kinase to regulate centrosome disjunction","volume":"12","author":"Mardin","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neo.2024.100974_bib0034","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-017-0392-4","article-title":"NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase","volume":"10","author":"Gu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.neo.2024.100974_bib0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ccr.2006.10.020","article-title":"A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth","volume":"11","author":"Bonnet","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2024.100974_bib0036","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bjc.6604554","article-title":"Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer","volume":"99","author":"Michelakis","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2024.100974_bib0037","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/bjc.2013.120","article-title":"Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib","volume":"108","author":"Sanchez","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2024.100974_bib0038","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1065817","article-title":"A phosphatase associated with metastasis of colorectal cancer","volume":"294","author":"Saha","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neo.2024.100974_bib0039","doi-asserted-by":"crossref","first-page":"e21344","DOI":"10.1096\/fj.202001920RR","article-title":"Phosphatase of regenerating liver-3 regulates cancer cell metabolism in multiple myeloma","volume":"35","author":"Abdollahi","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.neo.2024.100974_bib0040","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/ncb1767","article-title":"Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression","volume":"10","author":"Fu","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neo.2024.100974_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.03.007","article-title":"FOXM1: a small fox that makes more tracks for cancer progression and metastasis","volume":"92","author":"Khan","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.neo.2024.100974_bib0042","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1038\/s41388-022-02398-4","article-title":"FOXM1 regulates glycolysis and energy production in multiple myeloma","volume":"41","author":"Cheng","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2024.100974_bib0043","first-page":"153","article-title":"Increased fatty acid synthase is a therapeutic target in mesothelioma","volume":"7","author":"Gabrielson","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2024.100974_bib0044","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.leukres.2014.12.010","article-title":"Plasma fatty acid profile in multiple myeloma patients","volume":"39","author":"Jurczyszyn","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.neo.2024.100974_bib0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41585-022-00654-6","article-title":"Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets","volume":"20","author":"Tan","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.neo.2024.100974_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216352","article-title":"Fatty acids in cancer chemoresistance","volume":"572","author":"Qin","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.neo.2024.100974_bib0047","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmet.2014.01.019","article-title":"Cholesteryl ester accumulation induced by PTEN loss and PI3K\/AKT activation underlies human prostate cancer aggressiveness","volume":"19","author":"Yue","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.neo.2024.100974_bib0048","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00277-009-0849-9","article-title":"Hyperlipidemic myeloma: review of 53 cases","volume":"89","author":"Misselwitz","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.neo.2024.100974_bib0049","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000505992","article-title":"The association between metabolic syndrome and multiple myeloma","volume":"144","author":"Ragbourne","year":"2021","journal-title":"Acta Haematol."},{"key":"10.1016\/j.neo.2024.100974_bib0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00277-011-1246-8","article-title":"Low-density lipoprotein cholesterol suppresses apoptosis in human multiple myeloma cells","volume":"91","author":"Tirado-Velez","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.neo.2024.100974_bib0051","article-title":"Statins and cardiomyocyte metabolism, friend or foe?","volume":"10","author":"Somers","year":"2023","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.neo.2024.100974_bib0052","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1016\/j.clml.2020.07.003","article-title":"Statins reduce mortality in multiple myeloma: a population-based US study","volume":"20","author":"Afzal","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.neo.2024.100974_bib0053","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2006-09-047076","article-title":"Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation","volume":"109","author":"Dai","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.neo.2024.100974_bib0054","first-page":"1817","article-title":"Mevastatin-induced apoptosis and growth suppression in U266 myeloma cells","volume":"24","author":"Janosi","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1016\/j.neo.2024.100974_bib0055","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood-2003-12-4218","article-title":"The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase","volume":"104","author":"Schmidmaier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.neo.2024.100974_bib0056","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.neo.2024.100974_bib0057","doi-asserted-by":"crossref","first-page":"3D","DOI":"10.1016\/0002-9149(94)90626-2","article-title":"Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase","volume":"73","author":"Blum","year":"1994","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.neo.2024.100974_bib0058","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2362.1994.tb00984.x","article-title":"Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors","volume":"24","author":"Sehayek","year":"1994","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.neo.2024.100974_bib0059","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cancergen.2015.03.008","article-title":"Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells","volume":"208","author":"Karlic","year":"2015","journal-title":"Cancer Genet."},{"key":"10.1016\/j.neo.2024.100974_bib0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.neo.2024.100974_bib0061","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2016.68.3482","article-title":"Statins are associated with reduced mortality in multiple myeloma","volume":"34","author":"Sanfilippo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2024.100974_bib0062","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","article-title":"Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity","volume":"98","author":"Shipman","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.neo.2024.100974_bib0063","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1038\/onc.2010.131","article-title":"Lipid raft-targeted therapy in multiple myeloma","volume":"29","author":"Mollinedo","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2024.100974_bib0064","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1038\/oncsis.2015.49","article-title":"Lipid metabolic reprogramming in cancer cells","volume":"5","author":"Beloribi-Djefaflia","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.neo.2024.100974_bib0065","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrd4099","article-title":"Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond","volume":"12","author":"Kunkel","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neo.2024.100974_bib0066","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1586\/epr.11.2","article-title":"Lipid rafts: signaling and sorting platforms of cells and their roles in cancer","volume":"8","author":"Staubach","year":"2011","journal-title":"Expert. Rev. Proteomics"},{"key":"10.1016\/j.neo.2024.100974_bib0067","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1074\/jbc.273.7.4096","article-title":"Characterization of a human lysophosphatidic acid acyltransferase that is encoded by a gene located in the class III region of the human major histocompatibility complex","volume":"273","author":"Aguado","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neo.2024.100974_bib0068","first-page":"8428","article-title":"Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma","volume":"63","author":"Hideshima","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2024.100974_bib0069","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc952","article-title":"Molecular mechanisms of novel therapeutic approaches for multiple myeloma","volume":"2","author":"Hideshima","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2024.100974_bib0070","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.bbrc.2016.08.061","article-title":"Hepatic Elovl6 gene expression is regulated by the synergistic action of ChREBP and SREBP-1c","volume":"478","author":"Bae","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neo.2024.100974_bib0071","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbrc.2008.01.075","article-title":"Mouse Elovl-6 promoter is an SREBP target","volume":"368","author":"Kumadaki","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neo.2024.100974_bib0072","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11745-009-3320-8","article-title":"Development of a high-density assay for long-chain fatty acyl-CoA elongases","volume":"44","author":"Kitazawa","year":"2009","journal-title":"Lipids"},{"key":"10.1016\/j.neo.2024.100974_bib0073","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1073\/pnas.1217611110","article-title":"Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains","volume":"110","author":"Volmer","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neo.2024.100974_bib0074","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/bloodadvances.2020002578","article-title":"The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma","volume":"5","author":"Lipchick","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.neo.2024.100974_bib0075","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.leu.2404658","article-title":"Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells","volume":"21","author":"Caers","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2024.100974_bib0076","first-page":"11","article-title":"Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease","author":"Liu","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neo.2024.100974_bib0077","doi-asserted-by":"crossref","DOI":"10.3390\/life13112213","article-title":"Adiponectin: a promising target for the treatment of diabetes and its complications","volume":"13","author":"Begum","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.neo.2024.100974_bib0078","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1182\/blood-2011-01-330407","article-title":"Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease","volume":"118","author":"Fowler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.neo.2024.100974_bib0079","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/jbmr.3951","article-title":"Myeloma cells down-regulate adiponectin in bone marrow adipocytes Via TNF-Alpha","volume":"35","author":"Morris","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.neo.2024.100974_bib0080","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.neo.2024.100974_bib0081","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/0008-5472.CAN-20-1088","article-title":"Myeloma-modified adipocytes exhibit metabolic dysfunction and a senescence-associated secretory phenotype","volume":"81","author":"Fairfield","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2024.100974_bib0082","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41392-023-01569-3","article-title":"Amino acid metabolism in health and disease","volume":"8","author":"Ling","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neo.2024.100974_bib0083","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050675","article-title":"The diverse functions of non-essential amino acids in cancer","volume":"11","author":"Choi","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2024.100974_bib0084","doi-asserted-by":"crossref","first-page":"27698","DOI":"10.1038\/srep27698","article-title":"GCN2 contributes to mTORC1 inhibition by leucine deprivation through an ATF4 independent mechanism","volume":"6","author":"Averous","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neo.2024.100974_bib0085","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/bloodadvances.2020001639","article-title":"Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death","volume":"4","author":"Soncini","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.neo.2024.100974_bib0086","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.2019001034","article-title":"Amino acid metabolism in hematologic malignancies and the era of targeted therapy","volume":"134","author":"Tabe","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.neo.2024.100974_bib0087","first-page":"10","article-title":"Glutamine: metabolism and immune function, supplementation and clinical translation","author":"Cruzat","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.neo.2024.100974_bib0088","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway","volume":"496","author":"Son","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neo.2024.100974_bib0089","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.neo.2024.100974_bib0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2021.02.020","article-title":"Inhibition of the L-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors","volume":"507","author":"Prelowska","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.neo.2024.100974_bib0091","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40168-020-00854-5","article-title":"Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria","volume":"8","author":"Jian","year":"2020","journal-title":"Microbiome"},{"key":"10.1016\/j.neo.2024.100974_bib0092","first-page":"14","article-title":"Intestinal Klebsiella pneumoniae contributes to pneumonia by synthesizing glutamine in multiple myeloma","author":"Wang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2024.100974_bib0093","first-page":"12","article-title":"Myeloma cells deplete bone marrow glutamine and inhibit osteoblast differentiation limiting asparagine availability","author":"Chiu","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2024.100974_bib0094","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neo.2024.100974_bib0095","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2024.100974_bib0096","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1038\/onc.2015.464","article-title":"Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax","volume":"35","author":"Bajpai","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2024.100974_bib0097","first-page":"3","article-title":"Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies","author":"Gonsalves","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.neo.2024.100974_bib0098","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728222.2017.1279148","article-title":"The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma","volume":"21","author":"Giuliani","year":"2017","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.neo.2024.100974_bib0099","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s42255-020-00329-9","article-title":"The ins and outs of serine and glycine metabolism in cancer","volume":"3","author":"Geeraerts","year":"2021","journal-title":"Nat. Metab."},{"key":"10.1016\/j.neo.2024.100974_bib0100","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ncb3523","article-title":"When cancer needs what's non-essential","volume":"19","author":"Sullivan","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neo.2024.100974_bib0101","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.tibs.2014.02.004","article-title":"Serine and glycine metabolism in cancer","volume":"39","author":"Amelio","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.neo.2024.100974_bib0102","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10350","article-title":"Functional genomics reveal that the serine synthesis pathway is essential in breast cancer","volume":"476","author":"Possemato","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neo.2024.100974_bib0103","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-020-00196-w","article-title":"Targeting phosphoglycerate dehydrogenase in multiple myeloma","volume":"10","author":"Elsaadi","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.neo.2024.100974_bib0104","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjh.16503","article-title":"Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma","volume":"190","author":"Wu","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.neo.2024.100974_bib0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40170-017-0169-9","article-title":"Bortezomib resistance in multiple myeloma is associated with increased serine synthesis","volume":"5","author":"Zaal","year":"2017","journal-title":"Cancer Metab."},{"key":"10.1016\/j.neo.2024.100974_bib0106","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/s41467-023-37699-z","article-title":"Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma","volume":"14","author":"Kuang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2024.100974_bib0107","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1038\/s41467-022-31248-w","article-title":"Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance","volume":"13","author":"Xia","year":"2022","journal-title":"Nat. Commun."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:14:09Z","timestamp":1761484449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558624000113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":107,"alternative-id":["S1476558624000113"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2024.100974","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2024.100974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100974"}}